Sanjeev Zutshi, MD
Internal Medicine · Port Charlotte, FLNPI 1912013236
Payments from drug & device makers
Across 241 payments — averaging $3257.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$502K
- Genentech, Inc.$239K
- Eli Lilly$29K
- BD$11K
- AbbVie$720
- Novo Nordisk$530
- plus $2K from 28 others
Across 1 payment — averaging $109.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$110
What the payments were for
- Food & beverage$3,508100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 17 | $502,432 |
| Genentech, Inc. | 47 | $239,111 |
| Eli Lilly | 3 | $28,706 |
| BD | 2 | $11,480 |
| AbbVie(2 entities) | 38 | $720 |
| Novo Nordisk | 32 | $530 |
| GSK | 23 | $267 |
| Boston Scientific | 3 | $207 |
| Amgen | 12 | $201 |
| Pfizer | 10 | $189 |
| Bayer | 7 | $173 |
| Lilly USA, LLC | 9 | $164 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 7 | $135 |
| Pharming Healthcare, Inc. | 1 | $124 |
| Novartis | 5 | $76 |
| Sanofi | 1 | $68 |
| Amarin Pharma, Inc. | 3 | $55 |
| Exact Sciences | 1 | $34 |
| Abbott | 2 | $34 |
| Abiomed | 1 | $33 |
| Mylan Specialty L.p. | 2 | $31 |
| Cvrx, Inc. | 1 | $30 |
| Merck | 2 | $27 |
| Sunovion Pharmaceuticals Inc. | 1 | $26 |
| Johnson & Johnson | 2 | $26 |
| Dexcom, Inc. | 1 | $25 |
| Eisai Inc. | 1 | $25 |
| Otsuka America Pharmaceutical, Inc. | 1 | $21 |
| Axsome Therapeutics, Inc. | 1 | $21 |
| Biohaven Pharmaceuticals, Inc. | 1 | $21 |
| Astellas Pharma US Inc | 1 | $19 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $17 |
| Nestle Healthcare Nutrition Inc. | 1 | $13 |
| Currax Pharmaceuticals LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- WATCHMAN FLX$141
- VRAYLAR$124
- RUCONEST$124
How this compares
$785,051 in reported general payments places this provider in the 95th percentile of 8,530 internal medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 229 | $372,040 |
| EliquisApixaban | 234 | $330,346 |
| MounjaroTirzepatide | 108 | $150,021 |
| JardianceEmpagliflozin | 101 | $149,628 |
| FarxigaDapagliflozin Propanediol | 95 | $120,000 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 88 | $104,376 |
| EntrestoSacubitril/Valsartan | 50 | $71,342 |
| XifaxanRifaximin | 16 | $48,706 |
| XareltoRivaroxaban | 27 | $43,702 |
| JanumetSitagliptin Phos/Metformin Hcl | 33 | $36,639 |
| Repatha SureclickEvolocumab | 28 | $36,614 |
| TrulicityDulaglutide | 23 | $31,611 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 19 | $30,424 |
| Tresiba Flextouch U-200Insulin Degludec | 30 | $25,161 |
| JanuviaSitagliptin Phosphate | 19 | $24,986 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $530 | $372,040229 claims |
| PfizerEliquis, Paxlovid | $189 | $333,106270 claims |
| Lilly USA, LLCMounjaro, Trulicity | $164 | $181,632131 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $502,432 | $150,424114 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $267 | $119,018101 claims |
| NovartisEntresto | $76 | $71,34250 claims |
| MerckJanumet, Januvia | $27 | $61,62552 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $135 | $48,70616 claims |
| Johnson & JohnsonXarelto | $26 | $43,70227 claims |
| AbbVieLinzess, Synthroid | $720 | $31,278133 claims |
| Astellas Pharma US IncMyrbetriq | $19 | $17,37213 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,530 internal medicine providers in Florida.
Other internal medicine in Port Charlotte
- Yaneicy Gonzalez RojasCoral Gables$93.5M
- Juan Carlos RondonHollywood$66.8M
- Jaynier MoyaPembroke Pines$45.4M
- Mark KutnerMiami$35.7M
- Gilberto JimenezHialeah$35.6M
- Mira BaronWest Palm Beach$29.6M
- William SanchezHialeah$28.9M
- Nelia Sanchez-CrespoHollywood$28.8M
- Kwabena AyesuOrlando$27.6M
- Michael DeverWindermere$24M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.